Biologics are a fundamental therapeutic resource for patients with moderate to severe chronic plaque psoriasis because they well conjugate effectiveness and safety. Several classes of biologics are available, including TNF-α inhibitors (infliximab, etanercept, adalimumab and certolizumab pegol), IL-12/23 inhibitor (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab and brodalumab) and IL-23 inhibitors (guselkumab, risankizumab and tildrakizumab). Each class of biologics has distinct characteristics.

Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis / Gisondi, P; Bellinato, F; Conti, A; Dapavo, P; Piaserico, S; De Simone, C; Chiricozzi, A; Dattola, A; Malagoli, P; Malara, G; Campanati, A; Burlando, M; Esposito, M; Gallo, L; Girolomoni, G. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - (2020). [10.1111/jdv.16380]

Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis

Campanati, A;
2020-01-01

Abstract

Biologics are a fundamental therapeutic resource for patients with moderate to severe chronic plaque psoriasis because they well conjugate effectiveness and safety. Several classes of biologics are available, including TNF-α inhibitors (infliximab, etanercept, adalimumab and certolizumab pegol), IL-12/23 inhibitor (ustekinumab), IL-17 inhibitors (secukinumab, ixekizumab and brodalumab) and IL-23 inhibitors (guselkumab, risankizumab and tildrakizumab). Each class of biologics has distinct characteristics.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/276530
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 4
social impact